Does the presence of the fibronectin-aggrecan complex predict outcomes from lumbar discectomy for disc herniation?
Protein biomarkers associated with lumbar disc disease have been studied as diagnostic indicators and therapeutic targets. Recently, a cartilage degradation product, the fibronectin-aggrecan complex (FAC) identified in the epidural space, has been shown to predict response to lumbar epidural steroid injection in patients with radiculopathy from herniated nucleus pulposus (HNP).



Determine the ability of FAC to predict response to microdiscectomy for patients with radiculopathy due to lumbar disc herniation STUDY DESIGN/SETTING: Single-center prospective consecutive cohort study.



Patients with radiculopathy from HNP with concordant symptoms to MRI who underwent microdiscectomy.



Oswestry disability index (ODI) and visual analog scores (VAS) were noted at baseline and at 3-month follow-up. Primary outcome of clinical improvement was defined as patients with both a decrease in VAS of at least 3 points and ODI >20 points.



Intraoperative sampling was done via lavage of the excised fragment by ELISA for presence of FAC. Funding for the ELISA was provided by Cytonics, Inc.



Seventy-five patients had full complement of data and were included in this analysis. At 3-month follow-up, 57 (76%) patents were "better." There was a statistically significant association of the presence of FAC and clinical improvement (p=.017) with an 85% positive predictive value. Receiver-operating-characteristic (ROC) curve plotting association of FAC and clinical improvement demonstrates an area under the curve (AUC) of 0.66±0.08 (p=.037). Subset analysis of those with weakness on physical examination (n=48) plotting the association of FAC and improvement shows AUC on ROC of 0.81±0.067 (p=.002).



Patients who are "FAC+" are more likely to demonstrate clinical improvement following microdiscectomy. The data suggest that the inflammatory milieu plays a significant role regarding improvement in patients undergoing discectomy for radiculopathy in lumbar HNP, even in those with preoperative weakness. The FAC represents a potential target for treatment in HNP.
Orthopaedics Northeast, 5050 N. Clinton St. Fort Wayne, IN 46825, USA. Electronic address: wabashspine@gmail.com.
Micah W
MW
Smith
Department of Orthopaedic Surgery, Stanford University, 450 Broadway St, Redwood City, CA 94063, USA.
Agnes
A
Ith
Department of Orthopaedic Surgery, Stanford University, 450 Broadway St, Redwood City, CA 94063, USA.
Eugene J
EJ
Carragee
Department of Orthopaedic Surgery, Stanford University, 450 Broadway St, Redwood City, CA 94063, USA.
Ivan
I
Cheng
Department of Orthopaedic Surgery, Stanford University, 450 Broadway St, Redwood City, CA 94063, USA.
Todd F
TF
Alamin
Department of Orthopedics, Peace Health Oregon St. John- Orthopedics, 1615 Delaware St, Longview, WA 98632, USA.
S Raymond
SR
Golish
Department of Orthopaedic Surgery, Stanford University, 450 Broadway St, Redwood City, CA 94063, USA.
Kyle
K
Mitsunaga
Department of Orthopaedic Surgery, Stanford University, 450 Broadway St, Redwood City, CA 94063, USA.
Gaetano J
GJ
Scuderi
Department of Orthopaedic Surgery, Stanford University, 450 Broadway St, Redwood City, CA 94063, USA.
Matthew
M
Smuck
D000328:Adult; D053674:Aggrecans / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism; D017586:Diskectomy / Q000009:adverse effects*; D005260:Female; D005353:Fibronectins / Q000378:metabolism*; D006801:Humans; D055959:Intervertebral Disc Degeneration / Q000378:metabolism / Q000601:surgery*; D007405:Intervertebral Disc Displacement / Q000378:metabolism / Q000601:surgery*; D008159:Lumbar Vertebrae / Q000378:metabolism / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000175:diagnosis / Q000378:metabolism*
D053674:Aggrecans; D015415:Biomarkers; C067625:FN1 protein, human; D005353:Fibronectins
Biomarkers; Cytokines; Discectomy; Herniated nucleus pulposis; Lumbar